@FiercePharma: It's official: Roche's Perjeta nabs speedy FDA nod in early breast cancer. Kadcyla next? Story | Follow @FiercePharma
@CarlyHFierce: Bristol-Myers melanoma drug Yervoy helps patients live years longer, study finds. ICYMI yesterday | Follow @CarlyHFierce
> A former Morgan Stanley financial adviser pleaded guilty to insider trading after tipping off a friend about Gilead Sciences' ($GILD) plan to buy Pharmasset for $11.2 billion in 2011. Report
> Johnson & Johnson ($JNJ) reportedly received offers from major private equity firms for its Ortho Clinical Diagnostics unit. Report | More from FierceMedicalDevices
> Sanofi ($SNY) CEO Christopher Viehbacher told reporters in Mumbai that he expects global pricing pressures to continue. Report
> Mylan ($MYL) rolled out a generic version of Pfizer's ($PFE) antifungal liquid, Vfend oral suspension. Release
> What's tough for branded drugmakers is good for drugstore profits: Walgreen ($WAG) profits beat estimates on increased use of generic drugs. Report
> Teva Pharmaceutical Industries ($TEVA) launched its generic version of the AbbVie ($ABBV) drug for hyperparathyroidism in kidney patients, Zemplar. Report
> Prescription drug use among U.S. seniors has reached a plateau, and per-capita market growth in this age group is expected to slow. Report
@FierceMedDev: Drug-releasing intravaginal ring could help women control HIV prevention. Article | Follow @FierceMedDev
@MarkHFierce: Two U.S. insurers will now cover MDxHealth's prostate cancer Dx test--a major win. It's hard to get coverage. Press release | Follow @MarkHFierce
@MichaelGFierce: MIT nanoparticles help deliver vaccines to mucosal surfaces. More from FierceDrugDelivery | Follow @MichaelGFierce
> PerkinElmer expands MA life sciences research presence. Article
> Report: Blackstone, Bain, other equity firms bid for J&J's Dx unit. More
Biotech News
@FierceBiotech: Most popular story on our website in Sept.: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Story | Follow @FierceBiotech
@JohnCFierce: Pretty clear that Perlmutter now becomes the head wheeler dealer at Merck. Good role for him. Buying and selling. | Follow @JohnCFierce
@DamianFierce: Amid all this talk of axing jobs, have a look at FierceBiotech's rundown of just how much R&D chiefs get paid. Top 15 highest paid biopharma R&D chiefs | Follow @DamianFierce
> Serial NC startup team eyes another deal with latest biotech. More
> Struggling Merck slashing 8,500 jobs in major R&D, commercial reorganization. News
> Geron unloads its stem cell coffers to BioTime in stock deal. Story
> Shutdown looming, FDA approves new depression drug from Lundbeck, Takeda. Article
Biotech Research News
@EmilyMFierce: What happens to the FDA in a government shutdown? ICYMI from FierceBiotech | Follow @EmilyMFierce
> New approach could treat common childhood brain cancer. Report
> Antidepressants could provide new way to treat deadly lung cancer. More
> Antifungal drug abolishes HIV in cells. Article
> New approach could treat common childhood brain cancer. Story
> Evolva in talks with U.S. government for $14.7M antibacterial contract. Item
Pharma Manufacturing News
@EricPFierce: Growing Bayer HealthCare gets new leader. Pfizer exec Olivier Brandicourt takes over top job Nov. 1. ICYMI from FiercePharma | Follow @EricPFierce
> Legislation defines when FDA can take action against compounders. Story
> GSK opens $40M plant in Cork, Ireland, adding 20 jobs. More
> Merck joins Bahrain venture. News
> FDA plant inspections continue, even in government chaos. Item
> Boehringer Ingelheim Shanghai plant tripling capacity. Article
And Finally... Should vaccine makers resurrect the Lyme disease shot that mired GlaxoSmithKline ($GSK) in trouble more than a decade ago? Report (sub. req.)